Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-08 pm EDT			5-day change	1st Jan Change
134.46 ^USD	+3.33%		+3.38%	-12.07%

Jul. 07	Biogen estimated charge to impact eps by ($0.26) per share for q2	RE
Jul. 07	Biogen Faces Q2 Earnings Impact Due to $46 Million Charge	MT

Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat

Published on 02/12/2025 at 12:56, updated on 02/12/2025 at 12:57

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Biogen Inc.

Biogen estimated charge to impact eps by ($0.26) per share for q2	Jul. 07	RE
Biogen Faces Q2 Earnings Impact Due to $46 Million Charge	Jul. 07	MT
RBC Trims Price Target on Biogen to $208 From $213, Keeps Outperform Rating	Jul. 07	MT
Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy	Jun. 30	CI
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low	Jun. 30	RE
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low	Jun. 30	RE
Biogen Inc.(NasdaqGS:BIIB) added to Russell 1000 Value-Defensive Index	Jun. 30	CI
AbbVie to buy Capstan for up to $2.1 billion in immunology push	Jun. 30	RE
Biogen Inc.(NasdaqGS:BIIB) added to Russell 1000 Defensive Index	Jun. 30	CI
Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease	Jun. 30	MT
Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA	Jun. 27	CI
Biogen Reports Mobility Gains with New Nusinersen Dose for Spinal Disorder	Jun. 27	MT
Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says	Jun. 27	MT
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results	Jun. 25	CI
Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies	Jun. 25	MT
RBC Raises Price Target on Biogen to $213 From $205, Keeps Outperform Rating	Jun. 25	MT
Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025	Jun. 24	CI
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug	Jun. 24	RE
Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia	Jun. 18	CI
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment	Jun. 18	MT
Supernus enters depression drug market with up to $795 million Sage deal	Jun. 16	RE
Ionis Pharmaceuticals, Inc. Announces Executive Changes	Jun. 12	CI
Biogen: positive Phase 3 data in lupus	Jun. 12	CF
Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity	Jun. 12	MT
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus	Jun. 12	CI

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (74.6%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (6.7%) ; - other (18.7%): primarily revenues from partnership agreements.

Employees

7,605

Sector

Pharmaceuticals

Calendar

Jul. 22 - Q2 2025 Earnings Release (Projected)

More about the company